View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Lynn Hautekeete
  • Lynn Hautekeete

Immobel After the through, increase to Buy

Yesterday Immobel issued a trading update that gives comfort in the FY26 bond repayment of EUR 125.0m which was the biggest short term risk of the investment case. This triggered us to increase our TP from EUR 23.0 to EUR 28.0 with a BUY recommendation (prev. accumulate). The reasoning is explained in this new company note. We still don't think the dividend will come back in the next 2 years as the focus remains deleveraging. However, the share price reflected a dilutive capital raise which has ...

Jacob Mekhael ... (+4)
  • Jacob Mekhael
  • Lynn Hautekeete
  • Thomas Vranken
  • Wim Hoste
Thijs Berkelder
  • Thijs Berkelder
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Alfen: CEO intends to retire early. D'Ieteren: Belgian June car registrations down 16%, VW down only 5%, good mix. Euronext: Bearing gifts to Greeks. JDE Peet's: Instant Decaf

Guy Sips ... (+5)
  • Guy Sips
  • Livio Luyten
  • Michiel Declercq
  • Thibault Leneeuw
  • Wim Lewi
Mahaut Arnaud ... (+3)
  • Mahaut Arnaud
  • Paul de Froment
  • Thomas Mordelle

Alfen: CEO Marco Roeleveld to retire early

Yesterday, Alfen announced that CEO Marco Roeleveld will retire by year-end for medical reasons. Marco Roeleveld has been a key figure since 1997 and led Alfen’s IPO in 2018. The board has begun the search for his successor. This announcement comes after CCO Michelle Lesh stepped down in March 2025

Thibault Leneeuw
  • Thibault Leneeuw

Alfen Early retirement CEO

Alfen announced last evening that its CEO, Marco Roeleveld, will retire by the end of the year due to health reasons. Roeleveld, who led Alfen through its 2018 IPO and significant growth, emphasized that the decision, though difficult, is necessary to focus on his recovery. The Supervisory Board has initiated the search for a successor and expressed confidence in a smooth leadership transition. Alfen enters a transition phase where the appointment of a new CEO and the definition of a refreshed s...

Carole Braudeau
  • Carole Braudeau

Credit Morning 07/01/2025

Acqua e Sapone: high cash burn in Q1 and higher leverage|Flos B&B Italia Group dissolves its joint venture with Fendi|BBVA goes ahead with Sabadell offer|

Carole Braudeau
  • Carole Braudeau

Morning Crédit 01/07/2025

Acqua e Sapone : consommation de cash importante au T1 et hausse du levier|Flos B&B Italia met fin à sa JV avec Fendi|BBVA décide de poursuivre son offre sur Sabadell|

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Basic-Fit: Expands and extends banking facility. PostNL: USO mail proposal – step in right direction but timing late, no compensation. Umicore: Raises FY 2025 EBITDA guidance by c.9%

Jacob Mekhael ... (+6)
  • Jacob Mekhael
  • Livio Luyten
  • Michiel Declercq
  • Thomas Couvreur
  • Thomas Vranken
  • Wim Hoste

Morning Notes : ARGX BB, BFIT NA, PNL NA, QFG BB, UMI BB, BTLS BB, ONW...

: ARGX BB, BFIT NA, PNL NA, QFG BB, UMI BB, BTLS BB, ONWD BB, JDEP NA

 PRESS RELEASE

Total number of shares and voting rights in Zealand Pharma as of June ...

Total number of shares and voting rights in Zealand Pharma as of June 30, 2025 Company announcement – No. 16 / 2025 Total number of shares and voting rights in Zealand Pharma as of June 30, 2025 Copenhagen, Denmark, June 30, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar mo...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch